RHEUMATOLOGY
SPONSORED
EliA rheumatic disease tests
Best-in-class diagnostics that make a measurable difference
to the management of patients with rheumatic diseases
Sponsored by
Thermo Fisher
Scientific
Thermo Fisher Scientific –
committed to continuous
innovation
For almost 40 years, ImmunoDiagnostics (the
immunodiagnostics experts within Thermo Fisher
Scientific), previously known as Phadia, have
maintained position at the forefront of allergy
testing and become one of the world’s leading
autoimmune disease test providers.
Thermo Fisher Scientific develop, manufacture
and market complete blood test systems to enable
the clinical diagnosis and monitoring of allergy,
asthma and autoimmune diseases. Their range of
fully-automated systems supports healthcare
professionals and optimises efficiency in
laboratories worldwide. Always striving to provide
the most clinically relevant tests, they are
committed to continuous innovation to improve
patient outcomes.
12
HHE 2019 | hospitalhealthcare.com
The challenge of the rheumatic
disease patient
The often-vague and overlapping symptoms of
early rheumatic disease can make differentiation
challenging, 1 leading to an average time to
diagnosis of 6-42 months, disease dependent. 2-8
Delays in diagnosis are associated with poorer
patient outcomes, 9-17 so clinically relevant,
reliable testing is vital from the beginning.
Since rheumatic disease patients carry an
increased risk of comorbidities, including
other autoimmune conditions, cardiovascular
disease and malignancy, 18-20 early intervention
is key. 21-25
Early, accurate diagnosis can help reduce
the burden on the healthcare system
When patients suffer from non-specific symptoms
such as fatigue and arthralgia, tests for anti-
nuclear antibodies (ANA) by indirect
immunofluorescence or solid phase ANA screens,
anti-cyclic citrullinated peptide (anti-CCP)
antibodies, and rheumatoid factor (RF) are